Plastic and Reconstructive Surgery Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34100 Trieste, Italy.
Medicina (Kaunas). 2021 Feb 8;57(2):151. doi: 10.3390/medicina57020151.
Surgical site infection in implant-based breast reconstruction is a complication with variable incidence reported in the literature. Due to potential loss of implant and reconstruction, it can have a strong psychological impact on patients. This study aimed primarily at analyzing the current status of the surgical site infection (SSI), (type, time of onset, clinical presentation, pathogens and management) in patients who underwent implant-based breast reconstruction at our Breast Unit. Secondarily, we wanted to establish whether introduction of a new, updated evidence-based protocol for infection prevention can reduce SSI in implant-based breast reconstruction. A single-center retrospective study was performed primarily to evaluate the incidence and features of SSI after implant-based breast reconstruction from 2007 to 2020. In June 2020, a protocol for prevention of SSI in implant-based breast reconstruction was introduced in clinical practice. Secondarily, a data analysis of all patients who underwent implant-based breast reconstruction in compliance with this protocol was performed after preliminarily assessing its efficacy. 756 women were evaluated after mastectomy and implant-based breast reconstruction for breast cancer. A total of 26 surgical site infections were detected. The annual incidence of SSI decreased over time (range 0-11.76%). Data relating to infections' features, involved pathogens and implemented treatments were obtained. Since the introduction of the protocol, 22 patients have been evaluated, for a total of 29 implants. No early infections occurred. Surgical site infection rates at our Breast Unit are comparable to those reported in the literature. The SSI rates have shown a decreasing trend over the years. No SSI has occurred since the introduction of the prevention protocol for surgical site infection in June 2020.
植入物乳房重建术后的手术部位感染是一种并发症,文献中报道的发病率不同。由于可能会导致植入物和重建失败,因此会对患者造成强烈的心理影响。本研究主要旨在分析我们乳房科接受植入物乳房重建的患者的手术部位感染(SSI)的现状(类型、发病时间、临床表现、病原体和处理)。其次,我们想确定引入新的、更新的基于证据的感染预防方案是否可以降低植入物乳房重建中的 SSI 发生率。 进行了一项单中心回顾性研究,主要是评估 2007 年至 2020 年期间接受植入物乳房重建后 SSI 的发生率和特征。2020 年 6 月,在临床实践中引入了预防植入物乳房重建中 SSI 的方案。其次,在初步评估其疗效后,对所有符合该方案的接受植入物乳房重建的患者进行了数据分析。 在因乳腺癌接受乳房切除术和植入物乳房重建后,对 756 名女性进行了评估。共发现 26 例手术部位感染。SSI 的年发生率随时间呈下降趋势(范围 0-11.76%)。获得了有关感染特征、涉及病原体和实施治疗的数据。自该方案引入以来,共评估了 22 名患者,共 29 个植入物。未发生早期感染。 我们乳房科的手术部位感染率与文献报道的相似。SSI 发生率多年来呈下降趋势。自 2020 年 6 月引入预防手术部位感染方案以来,未发生 SSI。